

University of Groningen

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies

Van Not, Olivier J; van den Eertwegh, Alfons J M; Haanen, John B; van Rijn, Rozemarijn S; Aarts, Maureen J B; van den Berkmortel, Franchette W P J; Blank, Christian U; Boers-Sonderen, Marye J; van Eijs, Mick J M; de Groot, Jan-Willem B

Published in:
European Journal of Cancer

DOI:
[10.1016/j.ejca.2023.03.009](https://doi.org/10.1016/j.ejca.2023.03.009)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2023

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Van Not, O. J., van den Eertwegh, A. J. M., Haanen, J. B., van Rijn, R. S., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers-Sonderen, M. J., van Eijs, M. J. M., de Groot, J.-W. B., Hospers, G. A. P., Kapiteijn, E., de Meza, M., Piersma, D., Stevense-den Boer, M., van der Veldt, A. A. M., Vreugdenhil, G., Wouters, M. W. J. M., Suijkerbuijk, K. P. M., & Blokx, W. A. M. (2023). Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies. *European Journal of Cancer*, 186, 27-37. <https://doi.org/10.1016/j.ejca.2023.03.009>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Original Research

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies



Olivier J. Van Not ^{a,b,*}, Alfons J.M. van den Eertwegh ^c,
 John B. Haanen ^d, Rozemarijn S. van Rijn ^e, Maureen J.B. Aarts ^f,
 Franchette W.P.J. van den Berkmortel ^g, Christian U. Blank ^{d,h},
 Marye J. Boers-Sonderen ⁱ, Mick J.M. van Eijs ^{b,j},
 Jan-Willem B. de Groot ^k, Geke A.P. Hospers ^l, Ellen Kapiteijn ^m,
 Melissa de Meza ^{a,n,o}, Djura Piersma ^p, Marion Stevense-den Boer ^q,
 Astrid A.M. van der Veldt ^r, Gerard Vreugdenhil ^s,
 Michel W.J.M. Wouters ^{a,n,o}, Karijn P.M. Suijkerbuijk ^b,
 Willeke A.M. Blokx ^t

^a Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden 2333AA, The Netherlands

^b Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584CX, The Netherlands

^c Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, Amsterdam 1081HZ, The Netherlands

^d Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, The Netherlands

^e Department of Internal Medicine, Medical Centre Leeuwarden, Henri Dunantweg 2, Leeuwarden 8934AD, The Netherlands

^f Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, P. Debyealaan 25, Maastricht 6229 HX, The Netherlands

^g Department of Medical Oncology, Zuyderland Medical Centre Sittard, Dr. H. van der Hoffplein 1, Sittard-Geleen 6162BG, The Netherlands

^h Department of Medical Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, The Netherlands

ⁱ Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, Nijmegen 6525GA, The Netherlands

^j Center for Translational Immunology, University Medical Centre Utrecht, Lundlaan 6, Utrecht 3584EA, The Netherlands

^k Isala Oncology Center, Isala, Dokter van Heesweg 2, Zwolle 8025AB, The Netherlands

^l Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, Groningen 9713GZ, The Netherlands

^m Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, Leiden 2333ZA, The Netherlands

ⁿ Department of Biomedical Data Sciences, Leiden University Medical Centre, Einthovenweg 20, Leiden 2333ZC, The Netherlands

* Corresponding author: Postbus 85500, 3508 GA Utrecht, The Netherlands.

E-mail address: O.J.vanNot@umcutrecht.nl (O.J. Van Not).

^o Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, The Netherlands

^p Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, Enschede 7512KZ, The Netherlands

^q Department of Internal Medicine, Amphia Hospital, Molengracht 21, Breda 4818CK, The Netherlands

^r Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, 's-Gravendijkwal 230, Rotterdam 3015CE, The Netherlands

^s Department of Internal Medicine, Maxima Medical Centre, De Run 4600, Eindhoven 5504DB, The Netherlands

^t Department of Pathology, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584CX, The Netherlands

Received 12 January 2023; Received in revised form 3 March 2023; Accepted 12 March 2023

Available online 16 March 2023

KEYWORDS

Haematologic malignancy;
Melanoma;
Immune checkpoint inhibitors;
Response;
Survival

Abstract *Background:* Patients diagnosed with haematologic malignancies (HMs) have a higher risk of developing subsequent solid tumours, such as melanoma. Patients with HM were mostly excluded from clinical trials but potentially derive less benefit from immune checkpoint inhibitors (ICIs) due to disease- or treatment-related T- or B-cell dysfunction.

Methods: All advanced melanoma patients treated with anti-PD-1-based treatment or targeted therapy between 2015 and 2021 were included from the prospective nationwide Dutch Melanoma Treatment Registry. Progression-free survival (PFS) and melanoma-specific survival (MSS) were analysed for patients with HM (HM+) and without HM (HM-). A cox model was used to account for confounders associated with PFS and MSS.

Results: In total, 4638 advanced melanoma patients received first-line anti-PD-1 monotherapy (n = 1763), ipilimumab-nivolumab (n = 800), or BRAF(/MEK) inhibitors (n = 2075). Concurrent HMs were present for 46 anti-PD1-treated patients, 11 ipilimumab-nivolumab-treated patients and 43 BRAF(/MEK)-inhibitor-treated patients. In anti-PD-1-treated patients, the median PFS was 2.8 months for HM+ and 9.9 months for HM- (p = 0.01). MSS was 41.2 months for HM+ and 58.1 months for HM- (p = 0.00086). In multivariable analysis, the presence of an HM was significantly associated with higher risk of melanoma progression (HR_{adj} 1.62; 95% confidence interval [95% CI] 1.15–2.29; p = 0.006) and melanoma-related death (HR_{adj} 1.74; 95% CI 1.09–2.78; p = 0.020). Median PFS and MSS for first-line BRAF(/MEK-) inhibitor-treated HM+ and HM- patients were not significantly different.

Conclusions: Patients with HM and advanced melanoma show significantly worse melanoma-related outcomes when treated with ICI, but not targeted therapy, compared to patients without HM. Clinicians should be aware of potentially altered effectiveness of ICI in patients with active HM.

© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Patients diagnosed with haematologic malignancies (HMs) have a higher risk of developing certain types of second cancers, such as malignant melanoma [1,2]. Both B-cells and T-cells appear to play a role in obtaining a response to immune checkpoint inhibitors (ICIs) [3]. B-cells can present tumour-associated antigens to T-cells or produce antibodies benefitting anti-tumour response [4]. CD4⁺ T-cells mediate anti-tumour immunity through direct cytotoxicity and immunologic help for cytotoxic CD8⁺ T-cells and antibody responses [5,6]. Besides the induction of dysfunctional T-cell states by tumour antigen exposure, HMs, such as leukaemia and lymphoma, can contribute to impaired immune surveillance in several ways, including the promotion of a tolerogenic immune state [7]. B-cell lymphoma and chronic lymphocytic leukaemia (CLL) have also been found to be

accompanied by a decrease in T-helper cells and an increase in regulatory T-cell activity, which has been associated with a poor prognosis to cancer immunotherapy [8–10]. Newly developed immunotherapies such as checkpoint inhibitors are currently being evaluated in several HM such as classical Hodgkin lymphoma, B-cell lymphoma, and CLL [11,12]. In advanced melanoma, these immunotherapies have already led to an increase in survival [13]. The prognosis of patients with HM has also improved over the last years [14]. This increase in survival gives patients with HM more time to develop other types of cancer, and this patient group has already proven to be more prone to developing skin malignancies [1,2,15,16]. So far, little is known about the influence of HM on the response to anti-PD-1 treatment for solid tumours such as advanced melanoma. This nationwide study aimed to investigate the influence of HM on the objective response rate (ORR), progression-free survival

(PFS), overall survival (OS), and melanoma-specific survival (MSS) in advanced stage III and IV melanoma patients treated with anti-PD-1. We hypothesised that patients with both an HM and advanced melanoma have a worse anti-tumour response to ICI than melanoma patients without HM.

2. Materials and methods

Data were retrieved from the Dutch Melanoma Treatment Registry (DMTR). Since 2012, data from all systemically treated stage III and IV melanoma patients in the Netherlands has been registered in the DMTR [17]. We analysed all patients with advanced (i.e. unresectable) cutaneous melanoma who were treated with first-line checkpoint inhibitors (anti-PD-1 antibody monotherapy and ipilimumab-nivolumab combination therapy) or first-line BRAF(/MEK) inhibition registered in the DMTR between 2015 and 2021. Since ipilimumab monotherapy is no longer used as a first-line treatment, we did not include this treatment group. We compared patients with HM (HM+) and patients without HM (HM−). Since the status of the HM can be influential on the response to checkpoint inhibitors, additional data regarding the date of diagnosis, the disease status, and the treatment of the HM were retrieved from the electronic patient files of HM+ patients treated with first-line anti-PD-1. Baseline characteristics, ORR, and survival outcomes were compared between the two groups. The medical ethical committee approved research using DMTR data and concluded that it was not deemed subject to the Medical Research Involving Human Subjects Act in compliance with Dutch regulations. For this study, the dataset cut-off date was 7th December 2021.

2.1. Patient characteristics

The following baseline patient and tumour characteristics were analysed for all patients: age at diagnosis, gender, Eastern Cooperative Oncology Group Performance Status (ECOG PS), lactate dehydrogenase (LDH) levels, primary melanoma location, type of melanoma, Breslow thickness, ulceration, liver metastasis, brain metastasis, number of organ sites with metastases, stage according to American Joint Committee on Cancer 8th edition [18], and mutation status. Type of HM, diagnosis sequence (HM or primary melanoma), treatment for HM, and response to HM treatment are described for the HM+ group.

2.2. Statistical analysis

Descriptive statistics were used to analyse baseline characteristics. Pearson's chi-squared test was used to compare categorical variables, and the t-test or Mann-Whitney U test for continuous variables depending on

their distribution. The reversed Kaplan-Meier method was used to estimate median follow-up [19]. We calculated the ORR for the first treatment line for advanced melanoma. The treating physician determined the response evaluation according to the Response Evaluation Criteria in Solid Tumors version 1.1 [20]. The ORR was defined as the proportion of evaluable patients who achieved a complete response (CR) or partial response. Patients who did not have a response evaluation registered in the DMTR or who died from non-melanoma-related causes before their first response evaluation were excluded from the analysis of ORR. The Kaplan-Meier method was used to calculate median PFS, OS, and MSS. PFS was defined as start of systemic therapy for advanced melanoma to first progression of the melanoma or death. OS was defined as start of systemic therapy to death by any cause. MSS was defined as start of systemic therapy to melanoma-related death. Patients not reaching the end-point were right-censored at the date of the last contact. Cox proportional hazards models were used to estimate the association between HM and PFS/OS/MSS in a multivariable analysis. The variables for this analysis were selected based on earlier literature [21–23]. Factors used in multivariable analysis were age, gender, ECOG PS, LDH levels, liver metastasis, brain metastasis, number of organ sites with metastasis, and *BRAF* mutation status. Comparisons were considered statistically significant for two-sided p-values < 0.05. Statistical software used was R studio version 4.0.2 [24]; packages tableone [25], survival [26], and survminer [27].

3. Results

In total, 4638 advanced melanoma patients were included that were treated with first-line anti-PD-1 monotherapy (n = 1763), ipilimumab-nivolumab (n = 800), or BRAF(/MEK) inhibitors (n = 2075). Concurrent haematological malignancies were present at start of systemic treatment for 46 anti-PD1 treated patients, 11 ipilimumab-nivolumab treated patients and 43 BRAF(/MEK)-inhibitor-treated patients (Fig. 1). Median follow-up time was 34.2 months.

3.1. Patient characteristics

At baseline, patients with HM were significantly older and had worse ECOG PS than patients without HM. The distribution of the melanoma location was significantly different (p=0.003), and *BRAF* mutations were less frequent in the HM group (54.0% versus 65.7%; p=0.020). No other significant differences existed at baseline (Table 1). Patient characteristics per treatment type can be found in Supplementary Tables 1–3. In the HM+ group treated with anti-PD-1, the most frequent type of HM was non-Hodgkin's lymphoma (NHL) (n = 13; 29%), followed by CLL (n = 11;




Fig. 1. Flowchart of included patients.

24%). Information regarding the type of HM and the treatment of HM can be found in [Supplementary Table 4](#). Eighteen patients (39%) had a CR to HM treatment at the start of anti-PD-1 treatment for their advanced melanoma. Detailed information regarding the response to treatment at the time of anti-PD-1 treatment of the advanced melanoma can be found in [Supplementary Table 5](#).

3.2. Anti-PD-1

In the anti-PD-1 cohort, ORR to first-line treatment was 41% in the HM+ group and 55% in patients without HM ([Table 2](#)). The median PFS was 2.8 months (95% confidence interval [95% CI] 2.6–7.3) for patients with

HM and 9.9 months (95% CI 8.6–11.8) for patients without HM ($p = 0.01$) ([Fig. 2](#)). In multivariable analysis, being diagnosed with an HM was significantly associated with an increased risk of progression or death ($HR_{adj} 1.62$; 95% CI 1.15–2.29; $p = 0.006$) ([Fig. 3](#)). MSS was significantly longer for patients without HM. Median MSS was 41.2 (95% CI 12.8–NR) for HM+ patients and 58.1 months (95% CI 47.5–NR) for HM– patients ($p = 0.00086$) ([Fig. 4](#)). Adjusting for potential confounders showed a significant association between the presence of an HM and melanoma-related death ($HR_{adj} 1.74$; 95% CI 1.09–2.78; $p = 0.020$) ([Fig. 5](#)). Median OS was 12.8 months (95% CI 6.2–NR) for HM+. For HM–, median OS was significantly longer (32.3 months; 95% CI 29.1–35.8) ($p = 0.00033$)

Table 1

Patient characteristics comparison of patient and disease characteristics of anti-PD-1, ipilimumab-nivolumab and BRAF(/MEK) inhibitors treated advanced melanoma patients with and without haematologic malignancy.

	HM+ 100	HM– 4538	p-Value
Median age [IQR] ^a	70.5 [62.8, 77.0]	64.0 [54.0, 73.0]	< 0.001
Sex (%)			0.090
Male	69 (69.0)	2727 (60.1)	
Female	31 (31.0)	1811 (39.9)	
ECOG PS ^a (%)			0.012
0	39 (39.0)	1999 (44.1)	
1	27 (27.0)	1584 (34.9)	
≥2	25 (25.0)	641 (14.1)	
Unknown	9 (9.0)	314 (6.9)	
Melanoma location ^b (%)			0.003
Primary unknown	6 (6.0)	703 (15.5)	
Head-Neck	24 (24.0)	593 (13.1)	
Trunk	40 (40.0)	1876 (41.3)	
Extremities	26 (26.0)	1237 (27.3)	
Acral	4 (4.0)	85 (1.9)	
Unknown	0 (0.0)	44 (1.0)	
Melanoma type ^b (%)			0.605
Superficial spreading	46 (46.0)	1899 (41.8)	
Nodular	18 (18.0)	866 (19.1)	
Acral lentiginous	3 (3.0)	68 (1.5)	
Lentigo maligna	3 (3.0)	74 (1.6)	
Desmoplastic	1 (1.0)	18 (0.4)	
Other	3 (3.0)	114 (2.5)	
Unknown	26 (26.0)	1499 (33.0)	
Median Breslow thickness [IQR] ^b	2.5 [1.6, 4.0]	2.3 [1.3, 4.0]	0.557
Ulceration ^b (%)			0.034
No	48 (48.0)	1821 (40.1)	
Yes	27 (27.0)	1182 (26.0)	
Unknown	25 (25.0)	1535 (33.8)	
LDH levels ^a (%)			0.388
Not determined	2 (2.0)	99 (2.2)	
Normal	50 (50.0)	2632 (58.0)	
250–500	28 (28.0)	1136 (25.0)	
> 500	20 (20.0)	671 (14.8)	
AJCC stage (8th edition) ^a (%)			0.236
IIIc unresectable	6 (6.0)	306 (6.7)	
IV-M1a	4 (4.0)	321 (7.1)	
IV-M1b	14 (14.0)	481 (10.6)	
IV-M1c	53 (53.0)	1997 (44.0)	
IV-M1d	23 (23.0)	1412 (31.1)	
Unknown	0 (0.0)	21 (0.5)	
Liver metastases ^a (%)			0.164
No	59 (59.0)	3081 (67.9)	
Yes	39 (39.0)	1397 (30.8)	
Unknown	2 (2.0)	60 (1.3)	
Brain metastases ^a (%)			0.280
No	77 (77.0)	3105 (68.4)	
Yes, asymptomatic	9 (9.0)	636 (14.0)	
Yes, symptomatic	14 (14.0)	776 (17.1)	
Unknown	0 (0.0)	21 (0.5)	
Organ sites ^a (%)			0.154
< 3	42 (42.0)	2166 (47.7)	
≥3	56 (56.0)	2343 (51.6)	
Unknown	2 (2.0)	29 (0.6)	
Melanoma mutation status (%)			0.020

Table 1 (continued)

	HM+ 100	HM– 4538	p-Value
<i>BRAF</i>	54 (54.0)	2981 (65.7)	
<i>NRAS</i>	23 (23.0)	769 (16.9)	0.145
<i>KIT</i>	0 (0.0)	45 (1.0)	0.628
Systemic treatment			0.057
Anti-PD-1	46 (46.0)	1717 (37.8)	
Ipilimumab-nivolumab	11 (11.0)	789 (17.4)	
BRAF(/MEK) inhibitors	43 (43.0)	2032 (44.7)	

IQR: interquartile range;

ECOG PS: Eastern Cooperative Oncology Group Performance Status;

LDH: lactate dehydrogenase;

AJCC: American Joint Committee on Cancer.

^a Determined at time of advanced melanoma.

^b Determined at time of primary melanoma.

(Supplementary Figs. 1 and 2). Four (8.7%) HM+ and 329 (19.2%) HM– patients received BRAF(/MEK) inhibitors in a later line. Grade ≥3 anti-PD1 toxicity occurred in 17.4% of HM+ and 13.7% of HM– patients.

3.3. Ipilimumab-nivolumab

In first-line ipilimumab-nivolumab-treated patients, ORR was 36% for HM+ versus 52% for HM–. Although limited by small numbers, the same survival trends as in anti-PD-1-treated patients were seen in ipilimumab-nivolumab-treated patients. Median PFS was 2.3 months (95% CI 2.0–NR) for HM+ patients versus 6.8 (95% CI 5.5–9.2) for HM– patients. Median OS for HM+ patients was 4.6 months (95% CI 2.4–NR) and 31.7 months (95% CI 22.1–39.0) for HM– patients. Median MSS was 4.6 months (95% CI 2.4–NR) for HM+ patients and 46 months (95% CI 33.4–NR) for HM– patients. Grade ≥3 toxicity occurred in 36.4% of HM+ and 49.9% of HM– patients.

3.4. BRAF(/MEK) inhibitors

In patients treated with BRAF(/MEK) inhibitors, ORR was 50% in HM+ versus 48% in HM–. HM+ patients receiving targeted therapy had a median PFS of 4.7 months (95% CI 3.6–8.0), whereas HM– patients had a median PFS of 6.3 months (95% CI 6.0–6.6) (p = 0.078). For HM+ patients, median OS was 8.1 months (95% CI 6.0–15.3) and 9.4 months (95% CI 8.9–10.1) for HM– patients (p = 0.4). Median MSS in HM+ patients with a BRAF mutation and first-line treatment with BRAF(/MEK) inhibitors was 12.6 months (95% CI 8.1–44.2) and 11.8 months for HM– patients (95% CI 10.9–12.8) (p = 0.96) (Supplementary Figs. 3 and 4). Eighteen (41.9%) HM+ patients received checkpoint inhibitors in a later treatment line and 937 (46.1%) HM– patients. Grade ≥3 toxicity occurred more frequently in HM– than HM+ patients treated with BRAF(/MEK)

Table 2

Objective response rate comparison of first-line objective response rate (ORR) of anti-PD-1, ipilimumab-nivolumab, and BRAF/(MEK) inhibitors treated advanced melanoma patients with and without haematologic malignancy.

Objective response rate (ORR)	Anti-PD-1		Ipilimumab-nivolumab		BRAF/(MEK) inhibitors	
	HM+	HM-	HM+	HM-	HM+	HM-
CR	7 (17%)	360 (22%)	0 (0%)	97 (13%)	0 (0%)	93 (5%)
PR	9 (21%)	539 (32%)	4 (36%)	284 (39%)	20 (50%)	848 (43%)
SD	7 (17%)	300 (18%)	1 (9%)	88 (12%)	10 (25%)	566 (29%)
PD or melanoma-related death	19 (45%)	460 (28%)	6 (55%)	262 (36%)	10 (25%)	456 (23%)
ORR	16 (38%)	899 (54%)	4 (36%)	381 (52%)	20 (50%)	941 (48%)
Total (n)	42	1659	11	731	40	1963

CR: complete response;
 PR: partial response;
 SD: stable disease;
 PD: progressive disease;
 ORR: objective response rate (=CR + PR).

inhibitors (20.1% versus 7.0%), with skin toxicity being most frequent in the HM- group (n = 123; 6.1%) and pyrexia the most frequent in the HM+ group (n = 2; 4.7%).

3.5. Other survival outcomes

Furthermore, we investigated PFS and MSS in patients who had a CR to HM therapy at the time of anti-PD-1 initiation versus patients who did not have a CR. Although not significant, we did notice a trend towards better survival outcomes in patients who reached a CR (Supplementary Figs. 5 and 6).

4. Discussion

To our knowledge, this is the largest cohort study of first-line ICI or targeted therapy-treated patients with both an HM and advanced melanoma and the first to directly compare advanced melanoma patients treated with first-line ICIs or targeted therapy with and without HM. Patients with HM showed worse outcomes than patients without HM after ICI treatment, even after correcting for potential confounders. The results of our study confirm our hypothesis that patients with HM have worse melanoma-related outcomes upon ICI treatment than patients without HM. Interestingly, we




Fig. 2. Kaplan-Meier estimate of progression-free survival in anti-PD-1-treated advanced melanoma patients with and without haematologic malignancy.

Variable		N	Hazard ratio	p
Hematologic malignancy	No	1532	Reference	
	Yes	41	1.62 (1.15, 2.29)	0.006
Age	0-69	824	Reference	
	>70	749	1.13 (0.99, 1.28)	0.069
Gender	Male	982	Reference	
	Female	591	1.01 (0.89, 1.15)	0.880
ECOG	0-1	1465	Reference	
	2-4	108	1.43 (1.13, 1.80)	0.003
LDH	Normal	1202	Reference	
	250-500 U/l	317	1.22 (1.05, 1.42)	0.009
	>500 U/l	54	2.16 (1.59, 2.93)	<0.001
Liver metastasis	No	1253	Reference	
	Yes	320	1.23 (1.05, 1.43)	0.010
Brain metastasis	No	1339	Reference	
	Yes, asymptomatic	141	1.09 (0.88, 1.34)	0.444
	Yes, symptomatic	93	1.32 (1.03, 1.68)	0.028
Organsites	<3	1001	Reference	
	>2	572	1.25 (1.09, 1.44)	0.001
BRAF mutation	No	939	Reference	
	Yes	634	1.08 (0.95, 1.23)	0.237

Fig. 3. Cox proportional hazard model of progression-free survival in anti-PD-1-treated advanced melanoma patients with and without haematologic malignancy.

did not find significant differences in PFS and MSS between HM+ and HM- patients treated with BRAF (/MEK) inhibitors. Some of the HM+ patients in our cohort received chimeric antigen receptor-modified

(CAR) T-cell therapy or rituximab as a treatment for their HM. CAR T-cell therapy (which involves conditioning chemotherapy) can lead to cytopenias, such as lymphopenia [28,29], that may persist for several




Fig. 4. Kaplan-Meier estimate of melanoma-specific survival in anti-PD-1-treated advanced melanoma patients with and without haematologic malignancy.

Variable		N	Hazard ratio	p
Hematologic malignancy	No	1541	Reference	
	Yes	41	1.74 (1.09, 2.78)	0.020
Age	0-69	827	Reference	
	>70	755	1.21 (1.01, 1.45)	0.035
Gender	Male	988	Reference	
	Female	594	0.96 (0.80, 1.15)	0.647
ECOG	0-1	1473	Reference	
	2-4	109	1.60 (1.17, 2.19)	0.003
LDH	Normal	1210	Reference	
	250-500 U/l	318	1.32 (1.08, 1.62)	0.007
	>500 U/l	54	3.02 (2.09, 4.37)	<0.001
Liver metastasis	No	1259	Reference	
	Yes	323	1.57 (1.28, 1.93)	<0.001
Brain metastasis	No	1346	Reference	
	Yes, asymptomatic	141	1.39 (1.07, 1.82)	0.015
	Yes, symptomatic	95	1.97 (1.47, 2.65)	<0.001
Organsites	<3	1007	Reference	
	>2	575	1.33 (1.10, 1.61)	0.003
BRAF mutation	No	945	Reference	
	Yes	637	0.76 (0.63, 0.91)	0.003

Fig. 5. Cox proportional hazard model of melanoma-specific survival in anti-PD-1-treated advanced melanoma patients with and without haematologic malignancy.

months [28]. Treatment with rituximab, even after discontinuation, can result in prolonged B-cell depletion [30]. These therapy-induced cytopenias and consequently immunocompromised state may play a role in the poor outcomes of ICIs in HM+ patients. However, it is difficult to assess the clinical implications of these factors. A large, observational study including 151,949 patients showed a significantly elevated risk of developing primary cutaneous melanoma in patients with a history of large B-cell lymphoma (standardised incidence ratio of 1.22; 95% CI 1.02–1.45) or a history of Hodgkin lymphoma (standardised incidence ratio of 1.75; 95% CI 1.33–2.26). Survivors of most lymphoid neoplasm subtypes had a higher risk of death by any cause after a diagnosis of melanoma. Among survivors of melanoma, the diagnosis of a lymphoid neoplasm also increased the risk of death by any cause [31]. The cause of the poor outcomes in patients with HM remains to be fully elucidated, but dysregulation of the immune system in various manners, not limited to classically induced exhaustion as observed in solid tumours, seems to be an important factor [7,32]. Studies have focused on T-helper cells and regulatory T-cells as the cause of this immune dysregulation [8,9]. More recently, several studies have highlighted the importance of tertiary lymphoid structures and B-cells for response to checkpoint inhibition [33,34]. In our HM+ cohort, patients achieving a CR to HM therapy seem to perform better than patients who did not achieve a CR. Potentially this is due to the fact that these patients experience

less treatment- or disease-related B- and T-cell dysfunction than patients with an active HM. Brewer et al. [35] investigated the influence of having a history of CLL or NHL on the survival of malignant melanoma patients. In line with our findings, they reported a significantly worse OS and MSS for patients with both malignant melanoma and CLL or NHL. The same effect was described by Famenini et al. [36], who found melanoma patients with a history of CLL or NHL to have a higher risk of death than melanoma patients without CLL or NHL. However, both studies did not report the melanoma disease stage or the given treatment, which complicates comparison to our findings. Clinical studies investigating the response to checkpoint inhibitors in patients with both advanced melanoma and HM are rare, and patients suffering from HM were excluded from trials. Leiter et al. [37] conducted a retrospective multicentre study including 52 ICI-treated melanoma patients with concurrent HM, of whom 44 had unresectable melanoma, and eight received adjuvant ICI treatment for melanoma. In this unresectable group, ORR was 28.6%, median PFS was 8.4 months, and median OS was not reached. These patients were treated with either anti-PD-1 monotherapy (n = 32), anti-CTLA-4 monotherapy (n = 5), or a combination (n = 7). Six of these patients had received prior systemic melanoma therapy, making comparisons difficult since we only included patients treated first-line ICIs. An earlier study investigated whether developing CLL before or after malignant melanoma influenced mortality

rates. They found no differences in mortality rates between patients diagnosed with CLL before or after malignant melanoma [38]. Our study has some limitations. Firstly, population-based studies are generally more prone to missing data than clinical trials. However, data in the DMTR are registered by annually trained, independent data managers. The registered data are checked by treating physicians to further warrant the high quality. In addition, patients are registered in an online registry, which warns data managers when data are inconsistent or have missing values. The high quality and the low number of missing values of the DMTR have been demonstrated in an earlier study [17]. Secondly, observational studies are, by definition, prone to the introduction of bias, such as indication bias. Thirdly, despite adjusting for potential confounders in our multivariable analysis, residual confounding cannot be ruled out as a potential explanation for our findings. Fourthly, there is a broad spectrum of different HM and their therapies, ranging from chemotherapy to no treatment. This warrants caution when interpreting the outcomes of the HM+ group. Finally, the number of included patients is both a strength and a weakness in our study. Our cohort of patients with both HM and advanced melanoma is one of the largest described. Nonetheless, the number of included patients with HM remains small. Concluding, our results show that patients with both advanced melanoma and an HM have worse melanoma-related outcomes than advanced melanoma patients without an HM upon treatment with ICIs. Remarkably, this difference was not observed for targeted therapy-treated patients. Our findings stress the importance of studies analysing rare patient subgroups not represented in clinical trials, helping clinicians inform these patients of their chances of response and long-term survival.

Funding

For the Dutch Melanoma Treatment Registry (DMTR), the Dutch Institute for Clinical Auditing foundation received a start-up grant from governmental organisation The Netherlands Organization for Health Research and Development (ZonMW, project number 836002002). The DMTR is structurally funded by Bristol Myers Squibb, Merck Sharpe & Dohme, Novartis, and Roche Pharma. Roche Pharma stopped funding in 2019, and Pierre Fabre started funding the DMTR in 2019. For this work, no funding was granted.

CRedit authorship contribution statement

Van Not: Conceptualisation, Methodology, Formal analysis, Writing – Original Draft, Writing – Review & Editing. **Van den Eertwegh:** Writing – Review & Editing. **Haanen:** Writing – Review & Editing. **Van Rijn:** Writing – Review & Editing. **Aarts:** Writing – Review &

Editing. **Van den Berkmoortel:** Writing – Review & Editing. **Blank:** Writing – Review & Editing. **Boers-Sonderen:** Writing – Review & Editing. **Van Eijs:** Writing – Review & Editing. **De Groot:** Writing – Review & Editing. **Hospers:** Writing – Review & Editing. **Kapiteijn:** Writing – Review & Editing. **De Meza:** Conceptualisation, Writing – Review & Editing. **Piersma:** Writing – Review & Editing. **Stevensden Boer:** Writing – Review & Editing. **Van der Veldt:** Writing – Review & Editing. **Vreugdenhil:** Writing – Review & Editing. **Wouters:** Conceptualisation, Writing – Review & Editing, Supervision. **Suijkerbuijk:** Conceptualisation, Writing – Review & Editing, Supervision. **Blokx:** Conceptualisation, Writing – Review & Editing, Supervision.

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

A.vdE. has advisory relationships with Amgen, Bristol Myers Squibb, Roche, Novartis, MSD, Pierre Fabre, Sanofi, Pfizer, Ipsen, Merck and has received research study grants not related to this paper from Sanofi, Roche, Bristol Myers Squibb, Idera and TEVA and has received travel expenses from MSD Oncology, Roche, Pfizer and Sanofi and has received speaker honoraria from BMS and Novartis.

J.H. has advisory relationships with Achilles Therapeutics, AstraZeneca, Bristol Myers Squibb, BioNTech, Immunocore, Iovance Biotherapeutics, Instil Bio, Ipsen, MSD, Merck Serono, Molecular Partners, Novartis, Neogene Therapeutics, Pfizer, PokeAcel, Roche/Genentech, Sanofi, T-Knife and has received research grants not related to this paper from Asher Bio, Amgen, Bristol Myers Squibb, MSD, BioNTech, Neogene Therapeutics and Novartis. All grants were paid to the institutions.

C.B. has/had advisory role: BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures, received research funding: BMS, Novartis, NanoString, 4SC, stockownership: cofounder Immagene BV and Signature Oncology, patents (incl. submitted): WO 2021/177822 A1, N2027907, P091040NL2.

M.A. has advisory board/consultancy honoraria from Amgen, Bristol Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Astellas, Bayer. Research grants Merck-Pfizer. Not related to current work and paid to institute.

J.dG. has consultancy/advisory relationships with Bristol Myers Squibb, Pierre Fabre, Servier, MSD, Novartis.

G.H. consultancy/advisory relationships with Amgen, Bristol Myers Squibb, Roche, MSD, Pfizer, Novartis, Pierre Fabre and has received research grants

not related to this paper from Bristol Myers Squibb, Seerave and were paid to the institution.

E.K. has consultancy/advisory relationships with Bristol Myers Squibb, Novartis, Merck, Pierre Fabre, Lilly and Bayer, and received research grants not related to this paper from Bristol Myers Squibb and Pierre-Fabre. Not related to current work and paid to institute.

R.vR. has advisory board/consultancy honoraria from Pfizer and an expert meeting fee from Roche.

A.vdV. has consultancy relationships with Bristol Myers Squibb, MSD, Roche, Novartis, Pierre Fabre, Pfizer, Sanofi, Ipsen, Eisai, Merck.

M.B.S. has consultancy/advisory relationships with Pierre Fabre, MSD and Novartis.

K.S. has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, AbbVie, received honoraria from Novartis, MSD and Roche and received research funding from BMS, Philips and TigeTx.

All remaining authors have declared no conflicts of interest.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.ejca.2023.03.009](https://doi.org/10.1016/j.ejca.2023.03.009).

References

- [1] Landt-blom AR, Bower H, Andersson TML, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. *Leukemia* 2018;32(10):2203–10. <https://doi.org/10.1038/s41375-018-0027-y>.
- [2] Hisada M, Biggar RJ, Greene MH, Fraumeni JF, Travis LB. Solid tumors after chronic lymphocytic leukemia. *Blood* 2001;98(6):1979–81. <https://doi.org/10.1182/blood.V98.6.1979>.
- [3] Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Sautès-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. *Nat Rev Clin Oncol* 2022;19(7):441–57. <https://doi.org/10.1038/s41571-022-00619-z>.
- [4] Fridman WH, Petitprez F, Meylan M, et al. B cells and cancer: to B or not to B. *J Exp Med* 2021;218(1):1–11. <https://doi.org/10.1084/JEM.20200851>.
- [5] Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms. *Cancer Gene Ther* 2021;28(1–2):5–17. <https://doi.org/10.1038/s41417-020-0183-x>.
- [6] Oh DY, Fong L. Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox. *Immunity* 2021;54(12):2701–11. <https://doi.org/10.1016/j.immuni.2021.11.015>.
- [7] Curran EK, Godfrey J, Kline J. Mechanisms of immune tolerance in leukemia and lymphoma. *Trends Immunol* 2017;38(7):513–25. <https://doi.org/10.1016/j.it.2017.04.004>.
- [8] Christopoulos P, Pfeifer D, Bartholomé K, et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. *Blood* 2011;117(14):3836–46. <https://doi.org/10.1182/blood-2010-07-299321>.
- [9] D’Arena G, Laurenti L, Minervini MM, et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. *Leuk Res* 2011;35(3):363–8. <https://doi.org/10.1016/j.leukres.2010.08.010>.
- [10] Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. *Cell Res* 2017;27(1):109–18. <https://doi.org/10.1038/cr.2016.151>.
- [11] Kansara RR, Speziali C. Immunotherapy in hematologic malignancies. *Curr Oncol* 2020;27(S2):124–31. <https://doi.org/10.3747/co.27.5117>.
- [12] Annibaldi O, Crescenzi A, Tomarchio V, et al. PD-1 /PD-L1 checkpoint in hematological malignancies. *Leuk Res* 2018;67:45–55. <https://doi.org/10.1016/j.leukres.2018.01.014>.
- [13] Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. *J Clin Oncol* 2015;33(17):1889–94. <https://doi.org/10.1200/JCO.2014.56.2736>.
- [14] Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. *Blood Cancer J* 2020;10(5). <https://doi.org/10.1038/s41408-020-0323-4>.
- [15] Brewer JD, Shanafelt TD, Call TG, et al. Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia. *Int J Dermatol* 2015;54(8):e287–93. <https://doi.org/10.1111/ijd.12564>.
- [16] Blechman AB, Cabell CE, Weinberger CH, et al. Aggressive skin cancers occurring in patients treated with the Janus kinase inhibitor ruxolitinib. *J Drugs Dermatol* 2017;16(5):508–11 (<http://www.ncbi.nlm.nih.gov/pubmed/28628689>).
- [17] Jochems A, Schouwenburg MG, Leeneman B, et al. Dutch Melanoma Treatment Registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands. *Eur J Cancer* 2017;72:156–65. <https://doi.org/10.1016/j.ejca.2016.11.021>.
- [18] Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin* 2017;67(6):472–92. <https://doi.org/10.3322/caac.21409>. PMID:5978683.
- [19] Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. *Control Clin Trials* 1996;17(4):343–6. [https://doi.org/10.1016/0197-2456\(96\)00075-X](https://doi.org/10.1016/0197-2456(96)00075-X).
- [20] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45(2):228–47. <https://doi.org/10.1016/j.ejca.2008.10.026>.
- [21] van Breeschoten J, MWJM Wouters, Hilarius DL, et al. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. *Br J Cancer* 2021;124(7):1222–30. <https://doi.org/10.1038/s41416-020-01229-1>.
- [22] Van Zeijl MCT, JBAG Haanen, MWJM Wouters, et al. Real-world outcomes of first-line anti-PD-1 therapy for advanced melanoma: a nationwide population-based study. *J Immunother* 2020;43(8):256–64. <https://doi.org/10.1097/CJI.0000000000000334>.
- [23] van Zeijl MCT, de Wreede LC, van den Eertwegh AJM, et al. Survival outcomes of patients with advanced melanoma from 2013 to 2017: results of a nationwide population-based registry. *Eur J Cancer* 2021;144:242–51. <https://doi.org/10.1016/j.ejca.2020.11.028>.
- [24] R Core Team. *R: a language and environment for statistical computing*. 2017.
- [25] Yoshida K, Bartel A. Tableone: create “Table 1” to describe baseline characteristics with or without propensity score weights. 2020.
- [26] Therneau Terry M, Grambsch PM. *Modeling survival data: extending the Cox model*. New-York: Springer; 2000.
- [27] Kassambra Alboukadel, Kosinski Marcin, Biecek P. *Survminer: drawing survival curves using ggplot2*. 2020.

- [28] Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. *N Engl J Med* 2021;384(8):705–16. <https://doi.org/10.1056/nejmoa2024850>.
- [29] Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med* 2017;377(26):2531–44. <https://doi.org/10.1056/nejmoa1707447>.
- [30] Vikse J, Jonsdottir K, Kvaløy JT, Wildhagen K, Omdal R. Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases. *Rheumatol Int* 2019;1–8. <https://doi.org/10.1007/s00296-019-04272-1>.
- [31] Herr MM, Schonfeld SJ, Dores GM, et al. Mutual risks of cutaneous melanoma and specific lymphoid neoplasms: second cancer occurrence and survival. *J Natl Cancer Inst* 2018;110(11):1–11. <https://doi.org/10.1093/jnci/djy052>.
- [32] Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. *Blood* 2015;126(5):573–81. <https://doi.org/10.1182/blood-2015-03-567388>.
- [33] Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. *Nature* 2020;577(7791):561–5. <https://doi.org/10.1038/s41586-019-1914-8>.
- [34] Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. *Nature* 2020;577(7791):549–55. <https://doi.org/10.1038/s41586-019-1922-8>.
- [35] Brewer JD, Shanafelt TD, Otley CC, et al. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study. *J Clin Oncol* 2012;30(8):843–9. <https://doi.org/10.1200/JCO.2011.34.9605>.
- [36] Famenini S, Martires KJ, Zhou H, Xavier MF, Wu JJ. Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma. *J Am Acad Dermatol* 2015;72(1):78–84. <https://doi.org/10.1016/j.jaad.2014.09.030>.
- [37] Leiter U, Loquai C, Reinhardt L, et al. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. *J Immunother Cancer* 2020;8(2):1–10. <https://doi.org/10.1136/jitc-2020-000897>.
- [38] Brewer JD, Christenson LJ, Weenig RH, Weaver AL. Effects of chronic lymphocytic leukemia on the development and progression of malignant melanoma. *Dermatologic Surg* 2010;36(3):368–76. <https://doi.org/10.1111/j.1524-4725.2009.01447.x>.